Products
Cepeprubart Biosimilar Monoclonal Antibody (PSGL-1) for Research
Cat No.: GMP-Bios-INN-1129
Anti-SELPLG/CD162/PSGL1 therapeutic antibody (Pre-made Cepeprubart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Cepeprubart (development code SelK-2) is a monoclonal antibody targeting P-selectin glycoprotein ligand 1 (SELPLG). It is developed by Selexys for venous thromboembolism, asthma, pulmonary disease among others. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1129-1mg | 1mg | 3090 |
| GMP-Bios-INN-1129-10mg | 10mg | |
| GMP-Bios-INN-1129-100mg | 100mg | |
| GMP-Bios-INN-1129-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Cepeprubart biosimilar, Whole mAb, Anti-SELPLG/CD162/PSGL1 Antibody: Anti-SELPLG/CD162/P-selectin glycoprotein ligand 1/PSGL-1 therapeutic antibody |
| INN Name | Cepeprubart |
| Target | SELPLG/CD162/PSGL1 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2024 |
| Companies | Selexys |
| Conditions Approved | na |
| Conditions Active | Venous Thromboembolism;Asthma;Pulmonary Disease;Chronic Obstructive |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
